AIM: To describe the clinical results a prospective phase II study of radiosurgically treated @entity1 with recurrent @entity463 multiforme. @entity1 AND METHOD: Since 1986, 62 @entity1 were irradiated stereotactically. Including criteria were @entity41 < or = 5 cm and Karnofsky performance score > or = 70. Twenty-seven @entity1 (mean age 50 years) were treated for recurrent @entity5 . The planning target volume was defined by the contrast enhancing region demonstrated by magnetic resonance imaging (MRI) scans which were performed in treatment position. A safety margin of 2 to 5 mm was added. The mean dose was 17 Gy. The median interval from the time of initial diagnosis and therapy to radiosurgery for recurrent @entity5 was 9.6 months. Initial therapy consisted of surgery and irradiation (60 Gy). Survival curves were calculated according to the Kaplan Meier method. Quality of life was evaluated using objective criteria such as neurological findings, frequency of @entity410 and @entity134 medication. RESULTS: The median survival calculated from the time of diagnosis was 18 months, calculated from the time of radiosurgery 9 months. 4.5 months after therapy, 50% of the @entity1 showed improved or stable quality of life. CONCLUSION: Radiosurgery demonstrates efficacy in selected @entity1 suffering from recurrent @entity463 multiforme.

[The radiosurgery of XXXX multiforme in cases of recurrence. The Heidelberg experiences compared to the literature].

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures'] @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma']
@entity463 :: (MESH:D005909,Disease) :: ['glioblastoma']
